HER2-Directed Treatment Escalation or De-escalation Necessitates Careful Consideration in HER2+ Breast Cancer
Sara A. Hurvitz, MD, explains when de-escalation therapy can play a role in patients with HER2-positive breast cancer.
Sara A. Hurvitz, MD, explains when de-escalation therapy can play a role in patients with HER2-positive breast cancer.
Perioperative nivolumab improved responses in resectable non–small cell lung cancer, irrespective of the number of neoadjuvant treatment cycles completed.
Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC.
Steven E. Finkelstein, MD, DABR, FACRO, discusses the importance of disseminating treatment advancements and ongoing research in radiation oncology.
PT886 has been granted fast track designation for use as a potential therapeutic option in patients with metastatic claudin 18.2–positive pancreatic adenocarcinoma.
Shanta Dhar, PhD, FRSC, discusses the significance of being named a fellow of the National Academy of Inventors for her research in prostate cancer.
Ribociclib plus a nonsteroidal aromatase inhibitor bested nonsteroidal aromatase inhibitor therapy alone in terms of iDFS in early-stage breast cancer.
Avutometinib plus defactinib led to tumor regression in most heavily pretreated patients with recurrent low-grade serous ovarian cancer.
Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.
Komal L. Jhaveri, MD, FACP, presents key data on the addition of inavolisib to palbociclib and fulvestrant vs palbociclib and fulvestrant alone in select patients…
Faculty offer expert insights into emerging data on BTK inhibitor resistance in CLL, referencing earlier findings that indicate the potential existence of mutations before BTK…